Menopause is a natural stage of life that marks the end of a woman’s reproductive years. It usually occurs between the ages of 45 and 55, although it can happen earlier or later.
During this transition, the body produces lower levels of hormones such as estrogen and progesterone.
These hormonal changes can trigger a variety of symptoms that affect daily life, sleep, mood, and overall wellbeing.
One of the most common symptoms of menopause is vasomotor symptoms, a medical term that mainly refers to hot flashes and night sweats. Hot flashes are sudden feelings of intense heat that can spread through the face, neck, and upper body.
They may be accompanied by sweating, a rapid heartbeat, and feelings of discomfort. Night sweats are similar episodes that occur during sleep and can leave women waking up soaked and unable to rest properly.
Researchers estimate that about 80 percent of women experience hot flashes during menopause. For some women, the symptoms are mild and short-lived. For others, they can continue for years and significantly affect quality of life. Poor sleep, fatigue, mood changes, anxiety, and depression are often linked to these symptoms.
For decades, hormone therapy has been one of the most effective treatments for menopausal symptoms. However, not every woman can or wants to use hormone-based treatments. Some women have medical conditions that make hormone therapy unsuitable, while others prefer nonhormonal options. This has created a growing need for alternative treatments.
One of the newest options is a medication called fezolinetant. The drug is approved by the U.S. Food and Drug Administration and works differently from hormone therapy. Instead of replacing hormones, it targets specific brain pathways involved in regulating body temperature.
Now, new research suggests that the benefits of fezolinetant may extend beyond reducing hot flashes. The findings were presented at ENDO 2026, the annual meeting of the Endocrine Society held in Chicago.
The study was led by Pauline M. Maki, a professor of psychiatry, psychology, and obstetrics and gynecology at the University of Illinois Chicago College of Medicine.
According to Maki, this is the first real-world study to examine how nonhormonal menopause treatments affect hot flashes, sleep, mood, depression, and anxiety outside the controlled environment of clinical trials.
The research was part of an ongoing study called OPTION-VMS. The analysis included 656 women between the ages of 40 and 75 who were experiencing bothersome menopausal symptoms.
All participants had recently been prescribed nonhormonal treatments. Some received fezolinetant, while others were prescribed medications such as SSRIs, SNRIs, gabapentin, or oxybutynin.
The researchers monitored changes in symptoms over a period of 12 weeks. They assessed hot flashes and night sweats as well as symptoms of depression and anxiety.
Among the 201 women taking fezolinetant, the results were encouraging. Hot flashes and night sweats improved significantly by four weeks after treatment began. These improvements continued through eight weeks and twelve weeks.
Women also experienced meaningful reductions in symptoms of depression and anxiety. Improvements in mood were visible as early as four weeks and continued throughout the study period.
Women taking other nonhormonal treatments also showed improvements in depression and anxiety symptoms. However, the findings highlighted that fezolinetant performed well under real-world conditions, not just in carefully controlled clinical trials.
This distinction is important because participants in clinical trials are often healthier than the general population. Real-world studies include a broader range of patients and may better reflect what doctors and patients can expect in everyday medical practice.
The findings provide reassurance for women seeking alternatives to hormone therapy. Many women worry that nonhormonal treatments may be less effective than hormonal options. The study suggests that FDA-approved therapies such as fezolinetant can provide meaningful relief from both physical and emotional symptoms of menopause.
The research also highlights the strong connection between menopausal symptoms and mental health. Frequent hot flashes and poor sleep can contribute to stress, anxiety, and depression. By reducing these symptoms, treatments may help improve overall emotional wellbeing.
The study has several strengths, including a large sample size and a real-world design that reflects routine clinical care. However, the findings were presented at a scientific meeting and further peer-reviewed publications may provide additional details. The study was also sponsored by industry, which should be considered when interpreting the results.
Overall, the research suggests that fezolinetant may offer an important new option for women who cannot or do not wish to use hormone therapy.
The results indicate that the medication may improve not only hot flashes and night sweats but also symptoms of depression and anxiety, helping many women navigate menopause with greater comfort and confidence.
Review and analysis: The study provides valuable evidence that benefits seen in clinical trials may also occur in everyday medical practice. Its large sample size strengthens confidence in the findings.
However, because the research was industry-sponsored and presented at a conference, additional independent studies will be important for confirmation. Even so, the results suggest that nonhormonal treatments such as fezolinetant may become an increasingly important part of menopause care.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Source: University of Illinois Chicago.
